Suggested remit - To appraise the clinical and cost effectiveness of autologous haematopoietic stem cell transplantation (AHSTC) for previously treated relapsing-remitting multiple sclerosis.
Following on from information provided to NICE by the company in August 2017, the appraisal of Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1111
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 February 2023 | Discontinued. Following on from information provided to NICE by the company in August 2017, the appraisal of Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 01 May 2019 | This topic was not referred after the scoping exercise, the block scoping report summarising our advice to the Department of Health and Social Care regarding not referring this topic for appraisal is available here https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Block-scoping-reports/batch-block-scoping-report-B62.pdf |
| 27 July 2018 - 24 August 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 16 August 2017 | This topic is delayed pending further information |
| 17 May 2017 (00:00) | Scoping workshop (London) |
| 28 March 2017 | Draft scope documents |
For further information on our processes and methods, please see our CHTE processes and methods manual